| Literature DB >> 35893930 |
Thabani Sibiya1, Terisha Ghazi1, Anil Chuturgoon1.
Abstract
The human immunodeficiency virus (HIV) is one of the most prevalent diseases globally. It is estimated that 37.7 million people are infected with HIV globally, and 8.2 million persons are infected with the virus in South Africa. The highly active antiretroviral therapy (HAART) involves combining various types of antiretroviral drugs that are dependent on the infected person's viral load. HAART helps regulate the viral load and prevents its associated symptoms from progressing into acquired immune deficiency syndrome (AIDS). Despite its success in prolonging HIV-infected patients' lifespans, the use of HAART promotes metabolic syndrome (MetS) through an inflammatory pathway, excess production of reactive oxygen species (ROS), and mitochondrial dysfunction. Interestingly, Spirulina platensis (SP), a blue-green microalgae commonly used as a traditional food by Mexican and African people, has been demonstrated to mitigate MetS by regulating oxidative and inflammatory pathways. SP is also a potent antioxidant that has been shown to exhibit immunological, anticancer, anti-inflammatory, anti-aging, antidiabetic, antibacterial, and antiviral properties. This review is aimed at highlighting the biochemical mechanism of SP with a focus on studies linking SP to the inhibition of HIV, inflammation, and oxidative stress. Further, we propose SP as a potential supplement for HIV-infected persons on lifelong HAART.Entities:
Keywords: HAART toxicity; HAART/ARVs; HIV; MetS; Spirulina platensis; antioxidant; inflammation; oxidative stress
Mesh:
Year: 2022 PMID: 35893930 PMCID: PMC9332774 DOI: 10.3390/nu14153076
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Diagrammatic representation of Spirulina reduction of oxidative stress via several pathways. Spirulina inhibits NADPH oxidase, reduces ROS, blocks FR-induced apoptosis, and promotes mitochondrial health (Created with BioRender.com, accessed on 17 November 2021).
Figure 2The 2D chemical structures of phycocyanin, phycocyanobilin, bilirubin, and biliverdin (prepared by author using maestro 11.2).
Figure 3Antioxidant and anti-inflammatory effects of SP (created with BioRender.com, accessed on 17 November 2021).
HAART drugs mechanism and their adverse effects.
| HAART | Mechanism | Example | Adverse Effect |
|---|---|---|---|
| Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs) | NRTIs require intracellular phosphorylation via host enzymes before they can inhibit viral replication. These agents are nucleoside or nucleotide analogs with an absent hydroxyl at the 3′ end that are incorporated into the growing viral DNA strand. They competitively bind to reverse transcriptase and cause premature DNA chain termination as they inhibit 3′ to 5′ phosphodiester bond formation. | abacavir, didanosine, lamivudine, stavudine, tenofovir, emtricitabine, atazanavir, and zidovudine | Mitochondrial toxicity, bone marrow suppression, anemia, and lipodystrophy. |
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | NNRTIs bind to HIV reverse transcriptase at an allosteric, hydrophobic site. These agents cause a stereochemical change within reverse transcriptase, thus inhibiting nucleoside binding and inhibition of DNA polymerase. | delavirdine, efavirenz, nevirapine, rilpivirine | Temporary rashes but may progress to Stevens–Johnson’s syndrome. |
| Protease inhibitors (PIs) | PIs competitively inhibit the proteolytic cleavage of the gag/pol polyproteins in HIV-infected cells. These agents result in immature, noninfectious virions. PIs are administered with boosting agents such as ritonavir or cobicistat to patients that are failing their initial HAART combination. | atazanavir, darunavir, indinavir | Hepatotoxicity, insulin resistance, hyperglycemia, hyperlipidemia, lipodystrophy, and PR interval prolongation. |
| Integrase strand transfer inhibitors (INSTIs) | Integrase inhibitors bind viral integrase and prevent viral DNA from being incorporated into the host cell chromosome. | dolutegravir, elvitegravir, raltegravir | Some patients may experience dizziness, sleep disturbances, or depression. |
| Fusion inhibitors (FIs) | Fusion inhibitors bind to the envelope glycoprotein gp41 and prevent viral fusion to the CD4 T-cells. | enfuvirtide | Enfuvirtide is generally well tolerated though some patients may experience injection site reactions. |
| Chemokine receptor antagonists (CCR5 antagonists) | CCR5 antagonists selectively and reversibly block entry into the CD4 T-cells by preventing interaction between CD4 cells and the gp120 subunit of the viral envelope glycoprotein. | maraviroc | Some patients may experience dizziness or skin rashes. |
Abbreviations: HLA—human leucocyte antigen; CNS—central nervous system; GFR—glomerular filtration rate.